Lexeo Therapeutics (LXEO) Accumulated Expenses (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Accumulated Expenses data on file, last reported at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 689.84% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $8.2 million (up 689.84% YoY), and the FY2025 full-year result was $9.3 million, down 32.58% from the prior year.
• Accumulated Expenses retreated to $8.2 million in Q1 2026, from $9.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $15.7 million in Q3 2024 to a low of $1.0 million in Q1 2025.
• A 5-year average of $9.2 million and a median of $9.6 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 764.43% in 2024 and plunged 92.5% in 2025, its largest moves.
• Tracing LXEO's Accumulated Expenses over 5 years: stood at $6.4 million in 2022, then jumped by 68.85% to $10.8 million in 2023, then gained by 26.93% to $13.8 million in 2024, then plunged by 32.58% to $9.3 million in 2025, then slipped by 12.05% to $8.2 million in 2026.
• Business Quant data shows LXEO's Accumulated Expenses at $8.2 million in Q1 2026, $9.3 million in Q4 2025, and $9.9 million in Q3 2025.